Controversies in the antiphospholipid syndrome: Can we ever stop warfarin?

18Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Patients with antiphospholipid syndrome are at increased risk for recurrent arterial and venous thrombosis and therefore benefit from long term warfarin therapy. The optimal duration of warfarin therapy after a first venous thromboembolic event is however a matter of some controversy and many questions remain unanswered. After reviewing and analysing the available evidence, we discuss some common scenarios in everyday clinical practice where treatment decisions are difficult. © 2008 Fonseca and D'Cruz; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Fonseca, A. G., & D’Cruz, D. P. (2008). Controversies in the antiphospholipid syndrome: Can we ever stop warfarin? Journal of Autoimmune Diseases. https://doi.org/10.1186/1740-2557-5-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free